Update of ALDH As a Potential Biomarker and Therapeutic Target for AML

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2018 Mar 9

PMID 29516013

Citations 18

Authors

Xiangchou Yang

Rongxin Yao

Hong Wang

Affiliations

Soon will be listed here.

Abstract

Studies employing mouse transplantation have illustrated the role of aldehyde dehydrogenase (ALDH) defining hematopoietic stem cells (HSCs) and leukemia stem cells (LSCs). Besides being a molecular marker, ALDH mediates drug resistance in AML, which induces poor prognosis of the patients. In AML patients, either CD34ALDH population or CD34CD38ALDH population was found to denote LSCs and minimal residual disease (MRD). A bunch of reagents targeting ALDH directly or indirectly have been evaluated. ATRA, disulfiram, and dimethyl ampal thiolester (DIMATE) are all shown to be potential candidates to open new perspective for AML treatment. However, inconsistent results have been shown for markers of LSCs, which makes it even more difficult to differentiate LSCs and HSCs. In this review, we elevated the role of ALDH to be a potential marker to define and distinguish HSCs and LSCs and its importance in prognosis and target therapy in AML patients. In addition to immunophenotypical markers, ALDH is also functionally active in defining and distinguishing HSCs and LSCs and offers intracellular protections against cytotoxic drugs. Targeting ALDH may be a potential strategy to improve AML treatment. Additional studies concerning specific targeting ALDH and mechanisms of its roles in LSCs are warranted.

Citing Articles

The role of sirtuins in the regulation of reactive oxygen species in myocardial ischemia/reperfusion injury.

Wang Z, Zhao X, Lu M, Wang N, Xu S, Min D Mol Cell Biochem. 2025; .

PMID: 39920412 DOI: 10.1007/s11010-024-05204-9.

The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations.

Masciale V, Banchelli F, Grisendi G, Samarelli A, Raineri G, Rossi T J Biol Chem. 2024; 300(12):107994.

PMID: 39547513 PMC: 11714729. DOI: 10.1016/j.jbc.2024.107994.

Nanomedicine-based disulfiram and metal ion co-delivery strategies for cancer treatment.

Shen X, Sheng H, Zhang Y, Dong X, Kou L, Yao Q Int J Pharm X. 2024; 7:100248.

PMID: 38689600 PMC: 11059435. DOI: 10.1016/j.ijpx.2024.100248.

OGG1 as an Epigenetic Reader Affects NFκB: What This Means for Cancer.

Vlahopoulos S, Pan L, Varisli L, Dancik G, Karantanos T, Boldogh I Cancers (Basel). 2024; 16(1).

PMID: 38201575 PMC: 10778025. DOI: 10.3390/cancers16010148.

Fabrication of a three-dimensional bone marrow niche-like acute myeloid Leukemia disease model by an automated and controlled process using a robotic multicellular bioprinting system.

Alhattab D, Isaioglou I, Alshehri S, Khan Z, Susapto H, Li Y Biomater Res. 2023; 27(1):111.

PMID: 37932837 PMC: 10626721. DOI: 10.1186/s40824-023-00457-9.

References

Pearce D, Taussig D, Simpson C, Allen K, Rohatiner A, Lister T . Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells. 2005; 23(6):752-60. DOI: 10.1634/stemcells.2004-0292. View

Buchman C, Mahalingan K, Hurley T . Discovery of a series of aromatic lactones as ALDH1/2-directed inhibitors. Chem Biol Interact. 2015; 234:38-44. PMC: 4414788. DOI: 10.1016/j.cbi.2014.12.038. View

Sykes S, Kokkaliaris K, Milsom M, Levine R, Majeti R . Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia. Exp Hematol. 2015; 43(12):989-92. PMC: 5492948. DOI: 10.1016/j.exphem.2015.08.012. View

Fallon P, Gentry T, Balber A, Boulware D, Janssen W, Smilee R . Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantation. Br J Haematol. 2003; 122(1):99-108. DOI: 10.1046/j.1365-2141.2003.04357.x. View

Moreb J, Schweder M, Gray B, Zucali J, Zori R . In vitro selection for K562 cells with higher retrovirally mediated copy number of aldehyde dehydrogenase class-1 and higher resistance to 4-hydroperoxycyclophosphamide. Hum Gene Ther. 1998; 9(5):611-9. DOI: 10.1089/hum.1998.9.5-611. View

Hanekamp D, Cloos J, Schuurhuis G . Leukemic stem cells: identification and clinical application. Int J Hematol. 2017; 105(5):549-557. DOI: 10.1007/s12185-017-2221-5. View

Hoang V, Buss E, Wang W, Hoffmann I, Raffel S, Zepeda-Moreno A . The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients. Int J Cancer. 2014; 137(3):525-36. PMC: 4755039. DOI: 10.1002/ijc.29410. View

Schubert M, Herbert N, Taubert I, Ran D, Singh R, Eckstein V . Differential survival of AML subpopulations in NOD/SCID mice. Exp Hematol. 2010; 39(2):250-263.e4. DOI: 10.1016/j.exphem.2010.10.010. View

Purton L, Bernstein I, Collins S . All-trans retinoic acid enhances the long-term repopulating activity of cultured hematopoietic stem cells. Blood. 2000; 95(2):470-7. View

10.

Schuurhuis G, Meel M, Wouters F, Min L, Terwijn M, de Jonge N . Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS One. 2013; 8(11):e78897. PMC: 3823975. DOI: 10.1371/journal.pone.0078897. View

11.

Singh S, Brocker C, Koppaka V, Chen Y, Jackson B, Matsumoto A . Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress. Free Radic Biol Med. 2012; 56:89-101. PMC: 3631350. DOI: 10.1016/j.freeradbiomed.2012.11.010. View

12.

Januchowski R, Wojtowicz K, Zabel M . The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed Pharmacother. 2013; 67(7):669-80. DOI: 10.1016/j.biopha.2013.04.005. View

13.

Pal D, Kolluru V, Chandrasekaran B, Baby B, Aman M, Suman S . Targeting aberrant expression of Notch-1 in ALDH cancer stem cells in breast cancer. Mol Carcinog. 2016; 56(3):1127-1136. PMC: 7552110. DOI: 10.1002/mc.22579. View

14.

Al-Mawali A, Gillis D, Lewis I . Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones. J Hematol Oncol. 2016; 9(1):61. PMC: 4964068. DOI: 10.1186/s13045-016-0292-z. View

15.

Morgan C, Hurley T . Development of a high-throughput in vitro assay to identify selective inhibitors for human ALDH1A1. Chem Biol Interact. 2014; 234:29-37. PMC: 4414680. DOI: 10.1016/j.cbi.2014.10.028. View

16.

Gasparetto M, Smith C . ALDHs in normal and malignant hematopoietic cells: Potential new avenues for treatment of AML and other blood cancers. Chem Biol Interact. 2017; 276:46-51. DOI: 10.1016/j.cbi.2017.06.020. View

17.

Huang C, Tsai M, Chang T, Tang W, Chen S, Lai H . ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett. 2012; 328(1):144-51. DOI: 10.1016/j.canlet.2012.08.021. View

18.

Moreb J, Ucar-Bilyeu D, Khan A . Use of retinoic acid/aldehyde dehydrogenase pathway as potential targeted therapy against cancer stem cells. Cancer Chemother Pharmacol. 2016; 79(2):295-301. DOI: 10.1007/s00280-016-3213-5. View

19.

Muramoto G, Russell J, Safi R, Salter A, Himburg H, Daher P . Inhibition of aldehyde dehydrogenase expands hematopoietic stem cells with radioprotective capacity. Stem Cells. 2010; 28(3):523-34. PMC: 3909217. DOI: 10.1002/stem.299. View

20.

Xu B, Wang S, Li R, Chen K, He L, Deng M . Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2. Cell Death Dis. 2017; 8(5):e2797. PMC: 5520701. DOI: 10.1038/cddis.2017.176. View